Haemodynamic Management in 2026 SSC Guidelines: Vasopressor Strategies and Role of Vasopressin

The 2026 Surviving Sepsis Campaign guidelines emphasise individualised, physiology-driven management with earlier vasopressor use. Fluid resuscitation is guided by dynamic assessment rather than fixed volumes. Norepinephrine remains first-line, with vasopressin as an adjunct to reduce catecholamine exposure. Overall, care is shifting toward a more precise, patient-adapted haemodynamic strategy.

The 2026 update of the Surviving Sepsis Campaign (SSC) guidelines reinforces a continued shift toward individualised, physiology-driven management of septic shock. While the foundational principles of early recognition, infection control, and haemodynamic stabilisation remain unchanged, the updated recommendations place stronger emphasis on precision in resuscitation and vasopressor use.

Within this framework, haemodynamic management has evolved from a protocolised sequence toward a dynamic, patient-adapted strategy, where vasopressors are introduced earlier.

Fluid Resuscitation: From Standardisation to Individualisation

The guidelines maintain the importance of early fluid resuscitation, but move away from rigid, fixed-volume approaches. Instead, they emphasise on use of dynamic measures of fluid responsiveness, continuous reassessment of volume status and the avoidance of both hypovolaemia and fluid overload

This reflects increasing recognition that excessive fluid administration is associated with worse outcomes, and that early transition to vasopressor support may be appropriate in many patients.

Clinical implication

Vasopressors are no longer reserved for late-stage shock but are integrated earlier into the resuscitation pathway.

Early Vasopressor Therapy and Haemodynamic Targets

The SSC continues to recommend maintaining a mean arterial pressure (MAP) of at least 65 mmHg in patients with septic shock. However, the updated guidance places stronger emphasis on:

• Early initiation of vasopressors when hypotension persists despite initial fluids.
• Avoiding prolonged hypotension during resuscitation.
• Individualising targets in selected patient populations.

This reflects a broader conceptual shift: vasopressors are now seen as a core component of early stabilisation, rather than a rescue intervention.

Vasopressor Strategy: Hierarchy and Combination Therapy

Norepinephrine as First-Line Therapy

Norepinephrine remains the recommended first-line vasopressor over dopamine, epinephrine and selepressin, based on its efficacy and safety profile.

This position is unchanged, while the first-line use of norepinephrine over vasopressin and angiotensin II has been downgraded to a suggestion.

Vasopressin as Adjunctive Therapy

The 2026 guidelines continue to suggest vasopressin as a second-line adjunct to norepinephrine in patients “on escalating doses of norepinephrine”.

Importantly, vasopressin is not positioned as a replacement for norepinephrine, but as part of a combination vasopressor strategy.

Its primary roles include: 

• Reducing norepinephrine requirements.
• Supporting vascular tone through non-adrenergic mechanisms.

Although the formal recommendation remains largely unchanged, the clinical interpretation of vasopressin use is evolving.

Historically, vasopressin was often introduced late in the course of shock, in patients with hypotension refractory to catecholamines.

In contrast, current practice, reflected indirectly in the guidelines, supports consideration of vasopressin in: 

• Patients with increasing norepinephrine requirements.
• Situations where limiting catecholamine exposure is desirable.
• Persistent vasodilatory shock despite initial stabilisation.

This represents a shift from a rescue treatment to a more strategic adjunctive role.

Catecholamine-Sparing Strategy

A key concept underpinning vasopressin use is the reduction of catecholamine burden.

High-dose catecholamine therapy is associated with arrhythmias, increased myocardial oxygen demand and potential immunologic and metabolic effects

By enabling a reduction in norepinephrine dose, vasopressin contributes to a more balanced vasopressor approach, targeting vascular tone through complementary mechanisms.

Timing: Area of Ongoing Uncertainty

The SSC guidelines do not define a precise threshold for initiating vasopressin, leaving timing decisions to clinical judgment.

Current evidence suggests that earlier use may offer benefits in selected patients, but remains insufficient to support a strong, universal recommendation.

However, the guidelines mention that in the panellist’s practice,”85.1% of panel members add vasopressin in patients with septic shock on escalating doses of norepinephrine and that panellists using vasopressin initiate it at a median dose of 0.3 μg/kg/min of norepinephrine.”

Integration into Modern Haemodynamic Management

The broader evolution of the SSC guidelines toward phenotype-based and individualised care supports a more nuanced use of vasopressors.

In this context, vasopressin is best understood as:

• A complementary agent within multimodal haemodynamic management to reduce catecholamine burden
• A tool to address vasoplegia through non-adrenergic pathways.

Conclusion

The 2026 Surviving Sepsis Campaign guidelines do not fundamentally alter the formal positioning of vasopressin in septic shock. It remains recommended as a second-line adjunct to norepinephrine in patients requiring additional vasopressor support.

However, the broader evolution in haemodynamic management, characterised by earlier vasopressor use, individualised resuscitation, and increased awareness of catecholamine-related risks, enhances the clinical relevance of vasopressin within a modern treatment paradigm.

Rather than a late-stage intervention, vasopressin is increasingly integrated as a targeted component of combination vasopressor therapy, supporting a more balanced and physiologically grounded approach to septic shock management.

Key Points

• The 2026 Surviving Sepsis Campaign guidelines emphasise individualised, physiology-driven management, with a shift away from rigid protocols toward patient-specific haemodynamic strategies.
• Fluid resuscitation is no longer fixed volume; instead, it relies on dynamic assessment of fluid responsiveness to avoid both under-resuscitation and fluid overload.
• Vasopressors are introduced earlier in septic shock, with a strong focus on preventing prolonged hypotension and maintaining a target mean arterial pressure of at least 65 mmHg.
• Norepinephrine remains the first-line vasopressor, while vasopressin is recommended as a second-line adjunct, not a replacement, particularly when norepinephrine requirements are increasing.
• Vasopressin supports a catecholamine-sparing strategy, helping reduce risks associated with high-dose catecholamines.
• There is a shift in vasopressin use from a late “rescue” therapy to an earlier, strategic adjunct, although the optimal timing of initiation remains uncertain and dependent on clinical judgement. 

Disclaimer

Point-of-view articles are the sole opinion of the author(s) and are part of the ICU Management & Practice Corporate Engagement or Educational Community Programme.